Pathway activity was calculated for all breast cancer samples or for specific PAM50 subtypes (basal-like, HER2-enriched, luminal A and luminal B), segregated into primary lesions and metastases (Fig. 7a; Supplementary Fig. S9a). Here, ERBB2 is linked to breast carcinoma.